Firefly Neuroscience (AIFF) Cash from Financing Activities (2010 - 2026)

Firefly Neuroscience has reported Cash from Financing Activities for 10 years, with the latest figure at $7.9 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 595.24% year-over-year to $7.9 million in Q2 2026; TTM through Jun 2026 was $10.5 million, a 37.3% decrease from a year earlier, with the FY2025 full-year figure at $11.6 million, up 84.46% from the prior year.
• Cash from Financing Activities was $7.9 million for Q2 2026 at Firefly Neuroscience, up from $2.4 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $10.3 million in Q1 2025, with the low at -$87245.0 in Q2 2023.
• Average Cash from Financing Activities over 5 years is $2.1 million, with a median of $945000.0 recorded in 2024.
• The largest YoY upside for Cash from Financing Activities was 3303.21% in 2023 against a maximum downside of 1139.62% in 2023.
• Over 5 years, Cash from Financing Activities stood at $425000.0 in 2022, then surged by 404.94% to $2.1 million in 2023, then surged by 106.2% to $4.4 million in 2024, then slumped by 94.35% to $250000.0 in 2025, then jumped by 3056.4% to $7.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $7.9 million (Q2 2026), $2.4 million (Q1 2026), and $250000.0 (Q4 2025), per Business Quant data.